

Prescribed Opioid Use in Wisconsin 2008-2016: Findings From the Survey of the Health of Wisconsin

Tanvee Thakur, PhD, BPharm; Jodi H. Barnett, MS; Tamara LeCaire, MS, PhD; Andrew Bersch, MS; Paul Peppard, MS, PhD; Kristen Malecki, PhD, MPH; D. Paul Moberg, PhD

ABSTRACT

Background: The opioid epidemic is a national crisis. The objectives of this report were to describe prescription opioid use in Wisconsin from 2008 through 2016 using unique population-representative data and to assess which demographic, health, and behavioral health characteristics were related to past 30-day prescribed opioid use.

Methods: Data were obtained from the Survey of the Health of Wisconsin (SHOW), a statewide representative sample of 4,487 adults. Prescription medication use was ascertained via in-person interviews that included an inventory of all prescription medications used by the respondent in the past 30 days. The data were weighted to represent the adult population of Wisconsin, aged 21 to 74. Chi-square, logistic regression, and descriptive statistics were used to analyze data.

Results: From 2008 to 2016, 6.4% (95% CI, 5.5-7.3) of adults age 21 years or older reported using a prescribed opioid in the past 30 days. Hydrocodone was the most prescribed opioid class followed by oxycodone. People 50 years of age and older, self-identified black or Hispanic, urban dwellers, those with a high school education or less, and those having incomes below 200% of the federal poverty level (FPL) reported significantly higher rates of prescribed opioid use relative to others. Participants reporting physician-diagnosed drug or alcohol abuse, current smokers, and those currently suffering from depression also reported significantly higher use.

Conclusion: These data from 2008-2016 demonstrate concerning levels of prescription opioid use and provide data on which population groups may be most vulnerable. While policies and clinical practice have changed since 2016, ongoing evaluation of prescribing practices, including consideration of behavioral health issues when prescribing opioids, is called for.

• • •

Author Affiliations: University of Wisconsin-Madison School of Pharmacy, Madison, Wis (Thakur); Survey of the Health of Wisconsin, University of Wisconsin School of Medicine and Public Health, Madison, Wis (UW SMPH) (Barnett, LeCaire, Bersch, Malecki); Population Health Sciences, UW SMPH, Madison, Wis (Peppard, Malecki); Population Health Institute, UW SMPH, Madison, Wis (Moberg).

Corresponding Author: D. Paul Moberg, PhD, Research Professor and Senior Scientist, University of Wisconsin Population Health Institute, 610 Walnut St, 885 WARF Building, Madison, WI 53726; phone 608.263.1304; email dpmoberg@wisc.edu; ORCID ID 0000-0002-7475-7909.

INTRODUCTION

Opioids are a class of drugs that include the illegal drug heroin, synthetic opioids such as fentanyl, and pain relievers available legally by prescription, such as oxycodone (OxyContin), hydrocodone (Vicodin), codeine, morphine, and many others.¹ Opioids interact with nerve cells to relieve pain; prescription opioids are used to treat moderate to severe pain. They also produce pleasurable effects and are associated with serious risks of addiction, abuse, and overdose.² Opioid medications are subsequently prone to misuse, that is, taken in a manner or dose other than prescribed; used by other than the person being prescribed, even if for a legitimate medical complaint such as pain; or taken to feel euphoria (ie, to get high).² Roughly 21% to 29% of patients prescribed opioids for chronic pain misuse them, with 8% to 12% developing an opioid use disorder.³

Every day, on average, 130 people in the United States die after overdose on opioids, and more than 46 people die from an

overdose of prescription opioids.⁴ The Midwest, and specifically Wisconsin, is at increased risk. In Wisconsin, the rate of opioid use disorder more than tripled during 2005 to 2016.⁴ The Midwestern region as a whole more recently experienced a 70% increase in opioid overdose cases from July 2016 through September 2017.³ The death rate in Wisconsin attributed to opioid overdose has also been higher than the US overall; in 2016, 15.8 deaths per 100,000 persons occurred in Wisconsin compared to 13.3 deaths per 100,000 nationally.⁴

Wisconsin providers wrote 69.1 opioid prescriptions per 100

persons (4 million prescriptions) in 2015,⁴ similar to the average US rate of 70 opioid prescriptions per 100 persons.⁵ Opioid prescribing in Wisconsin has been reduced since 2016 (the last year of data in this study). The number of opiate prescriptions reported to the Prescription Drug Monitoring Program (PDMP) in 2019 declined by 13.7 % since 2016.⁶

While the rate of prescriptions and number of pills per prescription have declined, patients continue to head home daily from hospitals and clinics furnished with opioid pain prescriptions. After they have recovered from their procedures and no longer need opioid-based pain relief, roughly 70% of people hold on to their unused medication. The percentage of stockpiling rises to 86% for older adults.⁷ In Wisconsin, as many as 33% of all households may have unused opiates on hand.⁸ These unused pills are a primary source of diversion for nonmedical use and are a major source of prescription opioid abuse fueling the crisis of opioid addiction in the United States.^{9,10} Thus, in addition to potential harm to the individual patient, there is risk for prescribed opioids being diverted and misused.

Specific Aims/Objectives

The statewide representative Survey of the Health of Wisconsin (SHOW), which included data on prescription drug use, allowed an analysis estimating population-level prescribed opioid use and an examination of the characteristics of those who used these medications. Specifically, we (1) describe prescription opioid use in Wisconsin adults aged 21 to 74 during 2008-2016; and (2) assess which demographic, health, and behavioral health characteristics were related to past 30-day prescribed opioid use.

METHODS

Study Design


SHOW was funded beginning in 2006 by the Wisconsin Partnership Program to establish an infrastructure for annual statewide surveys to monitor the health and health determinants of Wisconsin residents.¹¹ A probability-based sampling approach is used to randomly select households and gather data on a wide variety of health conditions and exposures, as well as on health care access and utilization. SHOW includes an in-home interview, physical exam, and biospecimen collection. The program is modeled after the National Health and Nutrition Examination Survey (NHANES), which has provided key information on the nation's health for over 40 years. With the launch of SHOW, Wisconsin became the first state to monitor the health of its residents with an ongoing examination survey of this magnitude.

Details on SHOW's study design have been published previously.¹¹ In brief, survey participants are selected from a random sample of households using a probability-based cluster sampling approach. From the household sampling frame, addresses are selected using simple random sampling. Recruitment of SHOW participants begins with in-person contact by study staff at the

Table 1. Three-Year Groupings of Overall Reported Use of Prescription Opioids in the Past 30 Days

	N all	Opioid Use		
		n	%	95% CI
Overall	4487	321	6.4	5.5-7.3
2008-2010	1368	89	6.0	4.6-7.4
2011-2013	1591	115	6.5	5.0-8.0
2014-2016	1528	117	7.3	5.7-8.8

Figure. Prescribed Opioid Usage Within the Past 30 Days as Reported in the Survey of the Health of Wisconsin (SHOW)



*Total n = 4487, data weighted to reflect Wisconsin population ages 21 to 74. Differences between time periods were not significant at $P < .05$.

selected household address.¹¹ An effort is made during the recruitment process to enumerate all household members, and screen and enroll noninstitutionalized adults where the selected household was their place of residence for more than 6 months during that calendar year and who are mentally capable of informed consent and being interviewed.¹¹ There is no requirement that all eligible members of the household participate. Data collection continues throughout the year.

Data collection is divided into 3 major components: a private in-home interview, a self-administered questionnaire, and a mobile exam center or fixed clinic visit that includes biospecimen collection. SHOW enrolled participants aged 21 to 74 years in 2008-2013; beginning in 2014, adults aged 18 years or older were invited to participate. For comparability over time, the analyses here have been restricted to adults ages 21 to 74 years. All data collection protocols are approved by the University of Wisconsin Health Sciences Institutional Review Board (IRB ID# 2013-0251).

Survey Topics and Reporting

Topics covered in the surveys include demographics, such as age, sex, race, body mass index (BMI), education, employment status, poverty level, and geographical area, as well as information on health and health history, mental health, health care, health

Table 2. Specific Opioid Use Within the Past 30 Days by 3-Year Groupings

Type of Opioid	2008-2010 % (95% CI) n=1368	2011-2013 % (95% CI) n=1591	2014-2016 % (95% CI) n=1528	Overall % (95% CI) N=4487
Hydrocodone/ acetaminophen	2.19 (1.30–3.09)	2.59 (1.58–3.59)	3.40 (2.33–4.48)	2.55 (1.96–3.14)
Oxycodone	1.11 (0.41–1.81)	1.81 (1.00–2.61)	1.69 (1.25–2.12)	1.49 (0.87–1.86)
Hydrocodone	1.59 (0.67–2.51)	1.27 (0.57–1.97)	1.01 (0.60–1.43)	1.37 (0.87–1.86)
Oxycodone/ acetaminophen	0.31 (0.00–0.66)	0.54 (0.17–0.91)	0.71 (0.05–1.38)	0.47 (0.23–0.71)
Propoxyphene ^a	0.53 (0.19–0.87)	-	-	0.23 (0.08–0.37)
Acetaminophen/ codeine	0.41 (0.03–0.78)	0.54 (0.13–0.95)	0.32 (0.07–0.57)	0.45 (0.21–0.37)
Morphine sulphate	0.28 (0.00–0.62)	0.12 (0.00–0.26)	0.28 (0.05–0.51)	0.21 (0.05–0.37)
Fentanyl	0.05 (0.00–0.15)	0.17 (0.00–0.36)	0.19 (0.00–0.39)	0.12 (0.02–0.22)
Others ^b	0.21 (0.04–0.37)	0.24 (0.00–0.47)	0.48 (0.23–0.73)	0.26 (0.13–0.39)

^a Propoxyphene was banned from market in 2010 by the FDA.

^b "Others" were reported by fewer than 5 participants over the entire time period and included acetaminophen/propoxyphene, aspirin/butalbital/caffeine/codeine, cheratussin AC, codeine, codeine/phomethazine, hydrocodone/ibuprofen, hydromorphone, and norco.

insurance, behavioral health, and other economic and social determinants. Geographical area divisions followed the health regions defined by the Wisconsin Department of Health Services for data analysis.¹² For data regarding opioid medication use, participants were asked to show all bottles of their prescription medications they personally used in the past 30 days. The interviewer recorded verbatim the names of these medications and reviewed the list with the participant. Participants also were asked to recall any prescription medications taken within the past 30 days for which they no longer had the bottle; these also were recorded. The interviews did not collect data on the use of illicit drugs (including diverted prescribed opioids). For purposes of this analysis, the complete free-text list of all prescription medications recorded by interviewers was reviewed by a pharmacist with training in health services research. Medications that could be classified as opioids were identified. The National Library of Medicine's RxNorm system data for opioid or opioid-containing medications was reviewed and a listing of RxCUI (RxNorm Concept Unique Identifier) codes for opioid-containing medications was determined by the pharmacist. Medication names were matched to the specific RxCUI codes for opioid medications. Based on these data, each participant was coded as having used or not used prescribed opioids in the past 30 days.¹³

Analysis

All analyses were conducted in SAS[®] 9.4.¹⁴ The descriptive data were analyzed by cross-tabulation; chi-square and logistic regression were used to determine significance in differences of opioid use. All calculations were weighted to represent the population of Wisconsin and to adjust for spatial clustering and survey design-based factors.¹¹ Raw numbers of cases are reported in the tables, with weighted percentages. To smooth out year-to-year varia-

tion in sampling, 3-year intervals (2008-2010, 2011-2013, 2014-2016) were used for comparison over time. Differences in reported frequency of opioid use between the 3 time periods were assessed using chi-square statistics. Data also were analyzed for time by personal characteristic interactions using logistic regression.

Multivariate logistic regression modeling of opioid use by rural/urban classification was conducted with adjustments for demographic characteristics (sex, age, race), socioeconomic factors (education, poverty level), reported drug abuse, reported alcohol abuse, and health region. Interactions between rural/urban classification and the other model parameters were investigated.

RESULTS

Across all 9 years, 6.4% (95% CI, 5.5-7.3) of participants reported using a prescribed opioid in the past 30 days. Opioids were used by 6.0% (95% CI, 4.6-7.4) of individuals in 2008-2010 and by 7.3% (95% CI, 5.7-8.8) in 2014-2016 (Table 1). Differences over time in the percentage of people reporting use of prescription opioids in the past 30 days were not significant ($P=0.29$) when the 3 separate time intervals were compared (Figure).

Hydrocodone/acetaminophen was the most reported opioid medication across time, followed by oxycodone, hydrocodone, and oxycodone/acetaminophen (Table 2).

We examined opioid use by a number of participant characteristics. Except for sex, there was a significant ($P<0.05$) relationship of opioid use in each of the characteristics examined in Table 3. These variables were also examined for interaction with time to assess whether there were shifting patterns in the relationship between individual characteristics and rates of opioid use. The only significant interaction found was health region by time, with increased use in the Northern Region over this time period.

The mean age for people who reported opioid use (mean = 48.1 years, SD = 0.9 years) was higher than that of the overall sample (mean = 45.8 years, SD = 0.4 years). Prescription opioid use was significantly higher in people ages 50 and above relative to younger age groups. Married individuals had the lowest rate. People with higher BMIs (30+) reported higher rates of opioid use (9.0%) compared to those with BMIs < 30 (4.6%).

A significantly higher rate of prescription opioid use was reported by individuals self-reporting as black (11.5%) or Hispanic (9.8%) compared to white individuals (5.8%). People belonging to other races (8.8%) also showed significantly higher rates of prescribed opioid use.

People with higher education (bachelors or graduate degree)

Table 3. Characteristics Associated with Prescribed Opioid Use in the Past 30 Days

Characteristic	Level	N all	n	%	Opioid Use – Yes ^a		P value < 0.05
					LCL	UCL	
Overall	Overall	4487	321	6.4	5.5	7.3	
Sex	Male	1956	135	6.4	4.9	7.9	
	Female	2531	186	6.4	5.2	7.6	
Age (years)	21-49	2214	133	5.4	4.3	6.6	*
	50-74	2273	188	7.7	6.3	9.1	
Body Mass Index (kg/m ²)	<=29	2626	143	4.6	3.6	5.6	*
	30+	1802	169	9.0	7.1	11.0	
Racial and Hispanic status	White (non-Hispanic)	3863	255	5.8	4.9	6.8	*
	Black (Hispanic, non-Hispanic)	235	28	11.5	6.6	16.3	
	Hispanic (not black)	138	12	9.8	3.1	16.4	
	Other (none of the above)	251	26	8.8	3.9	13.7	
Marital status	Single/never married	721	52	6.1	4.2	7.9	*
	Married/living with partner	3048	182	5.4	4.4	6.4	
	Widowed	156	18	10.0	3.7	16.3	
	Divorced/separated	557	69	12.5	8.7	16.2	
Education level	High school or less	1182	115	8.7	6.6	10.8	*
	Some college or associate degree	1708	143	7.4	5.7	9.0	
	Bachelor's degree or more	1595	63	3.6	2.1	5.2	
Smoking status	Current	774	101	11.9	8.9	14.9	*
	Former	1216	100	7.3	5.5	9.0	
	Never	2424	112	4.1	3.1	5.1	
Employment status	Employed	2955	146	4.8	3.8	5.7	*
	Not employed, looking for work	270	20	6.5	2.8	10.1	
	Not employed, not looking for work	1248	152	11.3	9.0	13.7	
200% poverty level	Below	1212	141	10.2	8.1	12.3	*
	Above	3102	167	4.9	3.9	5.8	
Any health insurance in the past 12 months	No	302	25	6.9	3.7	10.1	
	Yes	4175	296	6.4	5.4	7.4	
Rural/urban classification	Urban	2298	183	7.5	6.1	9.0	*
	Suburban	735	49	6.1	3.7	8.6	
	Rural	1454	89	4.5	3.1	6.0	
Wisconsin region (DHS health regions)	Southeastern	1349	123	8.5	6.5	10.5	*
	Southern	843	39	4.1	2.5	5.7	
	Western	873	71	8.1	5.3	10.8	
	Northern	551	35	6.0	3.7	8.2	
	Northeastern	871	53	4.3	2.7	5.9	
Posttraumatic stress disorder (PTSD) diagnosis ^{b,c}	No	3321	213	6.2	5.2	7.2	*
	Yes	451	63	10.9	7.6	14.2	
Number of alcoholic drinks per week	0	1525	162	10.4	8.4	12.5	*
	1-7	1724	85	4.3	3.2	5.5	
	8-14	477	26	4.0	2.3	5.6	
	15+	370	20	5.9	2.1	9.7	
Doctor-diagnosed alcohol abuse ^b	No	3797	260	6.4	5.4	7.4	*
	Yes	155	28	14.8	7.5	22.0	
Doctor-diagnosed drug abuse ^b	No	3880	271	6.4	5.4	7.4	*
	Yes	72	17	22.1	9.5	34.7	
SF12: General health fair/poor	No	3879	181	4.3	3.5	5.1	*
	Yes	531	131	23.1	18.8	27.3	
Any chronic condition ^d	No	2506	102	4.3	3.3	5.4	*
	Yes	1897	214	9.5	8.0	11.1	
Depression ^e	No	3465	213	6.0	5.0	7.1	*
	Yes	304	58	14.5	9.9	19.0	

Abbreviations: LCL, 95% lower confidence limit, UCL, 95% upper confidence limit; DHS, Department of Health Services; TIA, transient ischemic attack.

* Chi-square *P* value < 0.05 for comparison of opioid use within participant characteristic.

^aIndividuals with more than 1 opioid prescription in the last 30 days were counted only once.

^bThis question was first asked starting in 2010.

^c Post-traumatic stress disorder diagnosis is based on scoring 14 or higher on the 6-item PCL-C (PTSD Checklist) Civilian version.

^dAny chronic condition includes heart attack or angina, stroke or TIA, diabetes, asthma, chronic bronchitis or emphysema, rheumatoid arthritis or osteoarthritis, or cancer.

^eDepression is determined from first 2 items on the Patient Health Questionnaire (PHQ)-9 depression screener, which asks about frequency of depressed mood and anhedonia over the past 2 weeks.

Table 4. Multivariate Model of Prescribed Opioid Use

Characteristic	Level	OR	LCL	UCL	P value
Sex (ref=men)	Women	1.12	0.75	1.69	0.58
Age (ref=21-49 years)	50-74 years	1.72	1.26	2.34	0.0007
Education ^a		0.80	0.63	1.03	0.08
Race (ref=white)	Black	0.82	0.42	1.60	0.56
	Hispanic (not black)	0.94	0.38	2.35	0.89
	Other (not black or Hispanic)	0.89	0.47	1.67	0.71
Drug abuse (ref=no)	Yes	1.57	0.75	3.28	0.23
Alcohol abuse (ref=no)	Yes	3.14	1.30	7.59	0.011
Poverty level (ref=above 200% FPL)	Below 200%	2.29	1.59	3.31	<0.0001
Health region (ref=Southeastern)	Southern	0.61	0.36	1.03	0.064
	Western	0.82	0.49	1.36	0.43
	Northern	1.19	0.69	2.03	0.52
Rural/urban classification (ref=urban)	Northeastern	0.44	0.27	0.72	0.001
	Suburban	0.95	0.61	1.47	0.81
	Rural	0.60	0.38	0.95	0.029

Abbreviations: OR, odds ratio; LCL, 95% lower confidence limit; UCL, 95% upper confidence limit; ref, reference group; FPL, federal poverty level.

^a Education was coded as a 3-level ordinal variable (high school to some college to college graduate).

used prescribed opioids at a rate significantly lower than people without a college degree (some college, high school or less) across all 9 years of data collection.

People who were not employed and not looking for work reported a significantly higher percentage of opioid medication use compared to those who were working or looking for jobs. There was a significant difference in opioid use by people who reported lower income levels. We used a cut-point of 200% federal poverty level (FPL); in 2015 this was \$23,540 for 1 person and \$8,320 for each additional household member.¹⁵ Among those below 200% FPL, 10.2% reported opioid use, compared to 4.9% of those who were above 200% FPL.

People from urban and suburban Wisconsin reported higher prescription opioid use compared to rural residents. The Southeastern and Western regions of the state had the highest rates of prescribed opiate use (8.5%; 8.1%).

We also examined health insurance status for its association with prescribed opiate use. There was very little difference in use of prescribed opiates among the 93.3% who were insured (6.4% opiate use) and the 6.7% who reported not having any health insurance in the past 12 months (6.9% opiate use). However, type of insurance was associated with prescribed opiate use—those with employer-sponsored health insurance had the lowest rate of opiate use (4.7%), while those with Medicare reported 12.3% opiate use, and those with Medicaid reported 13.5% past 30-day opiate use. Since type of insurance is highly related to age, income, and chronic conditions, this was not included in multivariate analysis.

A U-shaped relation was observed with significantly more people using prescribed opioids among those not consuming any alcohol (10.4% used opioids) and among those consuming the highest amounts of alcohol (5.9% used opioids), compared to about 4% opioid use among mild to moderate drinkers. Data were

collected beginning in 2010 on whether the participant reported having been medically diagnosed with alcohol abuse or drug abuse. Those medically diagnosed for alcohol abuse (14.8% used opioids) or drug abuse (22.1% used opioids) reported a significantly higher rate of prescription opioid use in the past month compared to those not diagnosed with either of these disorders (6.4% used opioids). Current and former smokers were also significantly more likely to use prescribed opiates than persons who had never smoked.

People who reported their health to be “fair or poor” had significantly higher opioid use (23.1%) relative to those reporting good, very good, or excellent general health (4.3%). Consistent with poor health, people who reported having chronic condi-

tions reported higher opioid use.

Multivariate analyses using logistic regression were performed to further investigate the significant results from the bivariate analysis. After adjustment, age, education, drug abuse, poverty level, health region, and urbanicity remained significantly related to the odds of prescription opioid use. Race, education, and alcohol abuse were no longer statistically significant at the $P=0.05$ level. Persons aged 50 and older were more likely to use prescription opioids (OR 1.72; 95% CI, 1.26-2.34) than younger people. Persons with household income below 200% FPL were significantly more likely to use prescribed opiates ($P= <0.0001$; OR 3.14; 95% CI, 1.30-7.59). Respondents in the Northeastern Region had significantly lower opioid use relative to the Southeastern Region (OR 0.44; 95% CI, 0.27-0.72), while those in the remaining regions did not significantly differ relative to the Southeastern Region. After adjusting for other variables, rural dwellers were significantly less likely to use prescribed opiates (OR 0.60; 95% CI, 0.38-0.95) than urban respondents. While there were differences in reporting prescription opioid use by race, these differences did not hold after adjustment for the related variables of education, urbanicity, and poverty level. Interactions between urbanicity and other variables in the model were examined; no statistically significant interactions were found between urban/rural status and any of the other model parameters.

DISCUSSION

Between 2008 and 2016, approximately 6.4% of Wisconsin residents reported using prescription opioids in the past 30 days. The prevalence of opioid use varied greatly by demographic factors; older individuals, persons of color and those who reported lower socioeconomic status had higher rates of opioid use.

These findings may be reflective of overall health status across the state's population. Use of opioids in the last 30 days is not reflective of abuse, but rather identifies populations at greater or lower risk of potential abuse and opioid diversion potential in households. These population estimates would be much higher if annualized, considering both new and refill prescriptions across the entire population. Another recent study found that 33% of respondents to a Wisconsin-based convenience survey had prescribed opioids in their homes.⁸ That study included unused opioids stockpiled in the home, while the SHOW survey specifically asked about prescriptions used in the past 30 days. These data highlight the high diversion risk of plentiful unused but retained prescribed opiates.

Examining levels of use over 3-year intervals, the slight increased trend in use over time was not significant at $P < 0.05$. While the rate of prescribed use was thus relatively stable, the Wisconsin Department of Health Services (DHS) reported that deaths due to opioid overdose increased in Wisconsin over these years, from 414 deaths in 2008 to 916 deaths in 2017 alone.⁴ These rates include both prescribed and illicit opiates.

Several of our results regarding the characteristics of those who use prescription opiates are easily explained. Older individuals (age 50 and above) suffer from more chronic conditions, have more medical procedures (in particular surgeries) and, hence, may require use of opioid pain relievers. Given this, seniors are at higher risks of overdose and dependency from opioids.¹⁶⁻¹⁸ In 2017, first responders transported almost 1000 Wisconsin seniors for suspected unintentional opioid overdose.⁴ The higher rate of prescribed opioid use reported by individuals who are unemployed and not looking for work is also easily explained. These may be retired older adults or individuals with severe chronic pain leading to unemployment. Similarly, participants who reported being in poor or fair health reported significantly more use of prescription opioids relative to those reporting good to excellent health. In this analysis, we were not able to differentiate opioid prescriptions for chronic versus acute conditions.

Several national studies have reported the existence of racial bias in opioid prescribing and use; African American and Hispanic individuals were perceived by prescribers to use more opioids but were prescribed fewer opioids than white individuals.¹⁹⁻²² Results from our study point to higher prescribed opioid use by black and Hispanic individuals. This contrast with evidence in the national literature warrants further investigation. While race/ethnicity became insignificant in our multivariate model, the collinear variables of urbanicity, Southeastern Wisconsin residence, and lower education and income remain as significant correlates of prescribed opioid use. These variables reflect socioeconomic determinants of health risk. The insignificance of race in this model likely reflects the strong association of race with residential patterns and socioeconomic status in

Wisconsin. The association of higher rates of prescribed opioid with this constellation of socioeconomic variables warrants further study.

Education is a well-established indicator of overall health and health literacy. The data show that as educational attainment went from high school graduate to some college to college graduate, the frequency of prescribed opioid use decreased. People with higher levels of education may be better informed about risks of opioids, may be healthier, have more access to preventive care, and/or may participate in conversations about pain management and opioid use with their health providers, which might lead to less prescribed opioid medication use than those with lower education levels.²³ This suggests a gap in knowledge, attitudes, and medication use practices of people related to their education level, a factor addressed in the health literacy literature as well as in literature on prescribed opioid use.²⁴⁻²⁷ It also may reflect a difference in provider prescribing patterns related to characteristics of the patient.

The bivariate data indicate significantly lower use of opioids in rural and suburban regions than in urban areas. This may reflect less access to providers in rural areas. After adjustment for urbanicity and other demographic variables, the Northeastern Region tended to yield lower prescribed opioid use than the Southeastern Region. Higher rates in the Southeastern Region are consistent with DHS reports of the highest ambulance runs due to opioid overdose in that region in 2018.⁴ Due to the interaction of urbanicity, health region, and other population characteristics, these results are tentative. A limitation of our data is the lack of information on illicit (non-prescribed, diverted or illegal) opiate use in this population.

Participants with diagnosed alcohol use disorders had significantly higher rates of prescription opioid use. Alcohol can interact with opioids, leading to adverse reactions that include respiratory depression, and can be fatal.²⁸ The Centers for Disease Control and Prevention (CDC) recommends that providers warn patients about risks of alcohol consumption when prescribing an opioid medication.¹ Pharmacists in Wisconsin are mandated by law to counsel patients with new and refill medications on current use, adverse effects, risks, and drug interactions every time the patient fills a prescription at the pharmacy.²⁹ Patients who are heavier alcohol users warrant more caution for clinicians prescribing opioids and enhanced counselling about medication interactions and risks. One of the more alarming findings of this study was the significantly higher rates of opioid use in people reporting doctor-diagnosed alcohol abuse and drug abuse. These findings are worrisome as they depict an acute need for communicating potential risks of opioids to these patients, which has been demonstrated in other nationwide studies as well.³⁰⁻³² It is possible that these patients were prescribed opioids without knowledge of their medical history and diagnoses.³³ Of some further concern in the behavioral health arena is the higher use

of opioids in people reporting clinical depression, given that opioids have been shown to aggravate depression.³⁴

Limitations

Although a rigorous sampling frame for inviting household participation was used, those agreeing to participate in SHOW may be a biased segment of the population. To overcome measurable bias, a weighting protocol was used to reflect the demographics of the state's population. The results are limited to the household dwelling population ages 21 to 74 years. While the actual prescription bottles were examined in most cases, a few participants self-reported the medications in absence of a pill bottle, which might have led to misreporting the medications used. Further, these results do not reflect nonprescribed opioid use, including illicit and diverted medications. The SHOW interview protocol did not include questions regarding illicit drug use; analysis of biospecimens would be necessary to assess the role of illicit opiate use. The data are limited to 2008 through 2016 interviews, so do not reflect recent changes in prescribing practices and policies, most notably limiting the total number of pills prescribed. Finally, the multivariate models are suggestive of patterns but due to multicollinearity of variables—in particular race, low income, and geographic location—these models are difficult to interpret.

Real time tracking of opiate prescribing behavior and forward extension of the time series data reported here should continue to assess the impact of changing policies and clinical practice. The SHOW data can be further exploited to provide population-level data on multiple health issues in Wisconsin in more depth than can be gleaned from administrative records. Analysis of SHOW data can provide professional and lay audiences with a more comprehensive understanding of the epidemiology of many health concerns.

CONCLUSION

This study is unique because the analysis reports on opioid prescription use based on representative respondent surveys and actual names of medications from pill bottles, rather than relying on medical records, self-report surveys, or administrative data such as the Prescription Drug Monitoring Program. A 2019 report⁶ indicates a recent reduction in opioid prescribing (including reduced number of pills prescribed). However, the rate of prescribed opiate use remained fairly constant over the 9 years of SHOW data with no significant reduction as of 2016 and, in 2019, 3.3 million prescriptions were written for opioids in Wisconsin.⁶ The recent reduction is unlikely to be sufficient to resolve the epidemic. The association of higher rates of prescribed opiates among individuals with behavioral health issues suggests the need for enhanced counseling and communication with patients about risks of these medications. Health providers should be vigilant of patient's health history—especially behav-

ioral health issues—when prescribing opioids, should apply the CDC guidelines, and communicate with patients about opioid risks. Patients with chronic conditions and behavioral health issues need to be given particular attention to assure adequate pain relief and consideration of alternative approaches to pain management. Clinical practice modification and public health and community initiatives, especially in the counties and areas reporting more opioid prescribing and use, should be undertaken to control the problem of prescription opioid overdose in the state.

Acknowledgments: The authors would like to thank the University of Wisconsin Survey Center; SHOW administrative, field, and scientific staff; and all the SHOW participants for their contributions to this study.

Funding/Support: Funding for the Survey of the Health of Wisconsin (SHOW) was provided by the Wisconsin Partnership Program PERC Award (233 PRJ 25DJ), the National Institutes of Health's Clinical and Translational Science Award (5UL RR025011), and the National Heart Lung and Blood Institute (1 RC2 HL101468). Awards from the Centers for Disease Control and Prevention (U17-CE002741) and the Substance Abuse and Mental Health Services Administration (U79-SP020781), via the Wisconsin Department of Health Services, provided partial support of Dr Moberg's participation in this effort.

Financial Disclosures: None declared.

REFERENCES

1. Communicating with patients: applying CDC's guideline for prescribing opioids. Centers for Disease Control and Prevention. Updated March 26, 2020. Accessed February 3, 2020. <https://www.cdc.gov/drugoverdose/training/communicating/>
2. Prescription opioids DrugFacts. National Institute of Drug Abuse. Updated May 2020. Accessed February 3, 2020. <https://www.drugabuse.gov/publications/drugfacts/prescription-opioid>
3. Opioid overdose crisis. National Institute on Drug Abuse. Updated May 27, 2020. Accessed February 3, 2020. <https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis>
4. Opioids: summary data dashboard. Wisconsin Department of Health Services. Updated March 23, 2020. Accessed February 3, 2020. <https://www.dhs.wisconsin.gov/opioids/dashboards.htm>
5. Wisconsin Department of Health Services. Select opioid-related morbidity and mortality data for Wisconsin. Published November 2016. Accessed February 3, 2020. <https://www.dhs.wisconsin.gov/publications/p01690.pdf>
6. Statistics: controlled substance dispensing. Wisconsin Department of Safety and Professional Services. Updated March 31, 2020. Accessed February 3, 2020. <https://pdmp.wi.gov/statistics/controlled-substance-dispensing>
7. Malani P KJ, Solway E. National Poll on Healthy Aging. University of Michigan. 2018. Published July/August 2018. Accessed June 24, 2020. https://deepblue.lib.umich.edu/bitstream/handle/2027.42/145684/NPHA-Opioids-Report_072518.pdf?sequence=1&isAllowed=y
8. Linnan S, Walsh-Felz A, Moberg DP. Perceptions, awareness, and use of substances in Wisconsin: results of a survey conducted for the Wisconsin Strategic Prevention Framework Partnerships for Success 2015. University of Wisconsin Population Health Institute. February 2018: 1-48. Accessed February 3, 2020. <https://uwmadison.app.box.com/s/jo0pmtxjqpisbut4zky2nsw83z2rly3>
9. Hill MV, McMahon ML, Stucke RS, Barth RJ, Jr. Hill MV, McMahon ML, Stucke RS, Barth RJ Jr. Wide variation and excessive dosage of opioid prescriptions for common general surgical procedures. *Ann Surg*. 2017;265(4):709-714. doi:10.1097/SLA.0000000000001993

10. McCabe SE, West BT, Boyd CJ. Leftover prescription opioids and nonmedical use among high school seniors: a multi-cohort national study. *J Adolesc Health*. 2013;52(4):480-485. doi:10.1016/j.jadohealth.2012.08.007
11. Nieto FJ, Peppard PE, Engelman CD, et al. The Survey of the Health of Wisconsin (SHOW), a novel infrastructure for population health research: rationale and methods. *BMC Public Health*. 2010;10:785. doi:10.1186/1471-2458-10-785
12. DHS regions by county. Wisconsin Department of Health Services. Updated July 26, 2018. Accessed February 3, 2020. <https://www.dhs.wisconsin.gov/aboutdhs/regions.htm>
13. Nelson SJ, Zeng K, Kilbourne J, Powell T, Moore R. Normalized names for clinical drugs: RxNorm at 6 years. *J Am Med Inform Assoc*. 2011;18(4):441-448. doi:10.1136/amiajnl-2011-000116
14. SAS/ACCESS® Interface to ADABAS. Version 9.4. SAS Institute Inc.; 2013.
15. Annual update of the HHS poverty guidelines. *Fed Regist*. 2015;80(14): 3236-3237. 42 USC § 9902(2). <https://www.govinfo.gov/content/pkg/FR-2015-01-22/pdf/2015-01120.pdf>
16. Vogel L. Seniors and self-harm factor in the opioid crisis. *CMAJ*. 2017;189(1):E42-E43. doi:10.1503/cmaj.109-5357
17. West NA, Severtson SG, Green JL, Dart RC. Trends in abuse and misuse of prescription opioids among older adults. *Drug Alcohol Depend*. 2015;149:117-121. doi:10.1016/j.drugalcdep.2015.01.027
18. West NA, Dart RC. Prescription opioid exposures and adverse outcomes among older adults. *Pharmacoepidemiol Drug Saf*. 2016;25(5):539-544. doi:10.1002/pds.3934
19. Singhal A, Tien YY, Hsia RY. Racial-ethnic disparities in opioid prescriptions at emergency department visits for conditions commonly associated with prescription drug abuse. *PLoS One*. 2016;11(8):e0159224. doi:10.1371/journal.pone.0159224
20. Pouget ER, Fong C, Rosenblum A. Racial/ethnic differences in prevalence trends for heroin use and non-medical use of prescription opioids among entrants to opioid treatment programs, 2005-2016. *Subst Use Misuse*. 2018;53(2):290-300. doi:10.1080/10826084.2017.1334070
21. Todd KH, Deaton C, D'Adamo AP, Goe L. Ethnicity and analgesic practice. *Ann Emerg Med*. 2000;35(1):11-16. doi:10.1016/s0196-0644(00)70099-0
22. Austin F, Toni MA. A 'rare case where racial biases' protected African-Americans. *New York Times*. November 25, 2019. Accessed November 26, 2019. <https://www.nytimes.com/2019/11/25/upshot/opioid-epidemic-blacks.html>
23. Parsells Kelly J, Cook SF, Kaufman DW, Anderson T, Rosenberg L, Mitchell AA. Prevalence and characteristics of opioid use in the US adult population. *Pain*. 2008;138(3):507-513. doi:10.1016/j.pain.2008.01.027
24. Ho JY. The contribution of drug overdose to educational gradients in life expectancy in the United States, 1992-2011. *Demography*. 2017;54(3):1175-1202. doi:10.1007/s13524-017-0565-3
25. Svendsen K, Fredheim OM, Romundstad P, Borchgrevink PC, Skurtveit S. Persistent opioid use and socio-economic factors: a population-based study in Norway. *Acta Anaesthesiol Scand*. 2014;58(4):437-445. doi:10.1111/aas.12281
26. Platts-Mills TF, Hunold KM, Bortsov AV, et al. More educated emergency department patients are less likely to receive opioids for acute pain. *Pain*. 2012;153(5):967-973. doi:10.1016/j.pain.2012.01.013
27. Krebs EE, Lurie JD, Fanciullo G, et al. Predictors of long-term opioid use among patients with painful lumbar spine conditions. *J Pain*. 2010;11(1):44-52. doi:10.1016/j.jpain.2009.05.007
28. Kreek MJ. Opioid interactions with alcohol. *Adv Alcohol Subst Abuse*. 1984;3(4):35-46. doi:10.1300/J251v03n04_04
29. Wis Admin Code Phar § 7.11-7.14.13 (2017).
30. Hughes HK, Korthis PT, Saha S, et al. A mixed methods study of patient-provider communication about opioid analgesics. *Patient Educ Couns*. 2015;98(4):453-461. doi:10.1016/j.pec.2014.12.003
31. Matthias MS, Krebs EE, Bergman AA, Coffing JM, Bair MJ. Communicating about opioids for chronic pain: a qualitative study of patient attributions and the influence of the patient-physician relationship. *Eur J Pain*. 2014;18(6):835-843. doi:10.1002/j.1532-2149.2013.00426.x
32. Smith RJ, Rhodes K, Paciotti B, Kelly S, Perrone J, Meisel ZF. Patient perspectives of acute pain management in the era of the opioid epidemic. *Ann Emerg Med*. 2015;66(3):246-252.e1. doi:10.1016/j.annemergmed.2015.03.025
33. Moss C, Bossano C, Patel S, Powell A, Chan Seay R, Borahay MA. Weaning from long-term opioid therapy. *Clin Obstet Gynecol*. 2019;62(1):98-109. doi:10.1097/GRF.0000000000000425
34. Sullivan MD. Depression effects on long-term prescription opioid use, abuse, and addiction. *Clin J Pain*. 2018;34(9):878-884. doi:10.1097/AJP.0000000000000632015;66:246-252.e241.

advancing the art & science of medicine in the midwest

WMJ

WMJ (ISSN 1098-1861) is published through a collaboration between The Medical College of Wisconsin and The University of Wisconsin School of Medicine and Public Health. The mission of *WMJ* is to provide an opportunity to publish original research, case reports, review articles, and essays about current medical and public health issues.

© 2020 Board of Regents of the University of Wisconsin System and The Medical College of Wisconsin, Inc.

Visit www.wmjonline.org to learn more.